Calamos Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Calamos Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-33,534	Closed	-$1.63M	–	703
2020 Q2	$1.63M	Sell	33,534 -39,254	-54%	-$1.88M	0.01%	599
2020 Q1	$3.08M	Buy	+72,788	New	+$3M	0.02%	482

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Calamos Advisors's ACAD Position: Q3 2020 in Review

Calamos Advisors sold out of Acadia Pharmaceuticals (ACAD) in Q3 2020, closing a stake of 33,534 shares — an estimated $1.63M sold.

Calamos Advisors first reported a position in ACAD in Q1 2020 and held it in 2 quarters. The position peaked at $3.08M in Q1 2020. 267 funds tracked by Wall St. Rank hold ACAD as of Q3 2020.

Calamos Advisors reported no remaining Acadia Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Calamos Advisors sold 33,534 Acadia Pharmaceuticals shares in Q3 2020, an estimated $1.63M.
Calamos Advisors first reported a position in Acadia Pharmaceuticals in Q1 2020 and held it in 2 quarters.
Calamos Advisors's Acadia Pharmaceuticals position peaked at $3.08M in Q1 2020.
267 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2020.

Based on Calamos Advisors's 13F filing for Q3 2020, filed 26 Oct 2020.